An interventional study of home-based telerehabilitation group and center-based traditional rehabilitation group in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Status unknown at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-16.
Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Treatment
Chronic obstructive pulmonary disease(COPD) patients could benefit from pulmonary rehabilitation(PR) in better managing of the disease and its symptoms and in avoiding future relapses and hospitalizations. However, due to a large number of drop outs from PR, lack of professionals, and the (Corona Virus Disease 2019) COVID-19 epidemic, the PR has been underutilized, leading to a need for investigation of updated forms. The study aims to investigate the effects of a home-based PR program using minimal accessories, facilitated with wearable activity trackers and smartphones.
4,253 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 707 are open to participants now.
This study's planned enrollment of 360 is above the median of 70 across 3,008 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →China-Japan Friendship Hospital is the lead sponsor of 177 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with a clinical diagnosis of and meeting the following criteria are eligible:
Exclusion Criteria:
Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises.
Behavioral: home-based telerehabilitation group
Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.
Behavioral: center-based traditional rehabilitation group
Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment. The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group.
6-minute walk distance (6MWD)
6-minute walk distance
Time frame: 8 weeks; 20 weeks
pulmonary function
forced expiratory volume in 1 second (FEV1) \[velocity\]
Time frame: 8 weeks; 20 weeks
pulmonary function
ratio between FEV1 and forced vital capacity (FEV1/FVC) \[velocity\]
Time frame: 8 weeks; 20 weeks
pulmonary function
forced expiratory flow between 25 and 75% of forced vital capacity (FEF25-75%) \[velocity\]
Time frame: 8 weeks; 20 weeks
pulmonary function
inspiratory capacity (IC) \[velocity\]
Time frame: 8 weeks; 20 weeks
pulmonary function
residual volume (RV) \[velocity\]
Time frame: 8 weeks; 20 weeks
pulmonary function
total lung capacity (TLC) \[velocity\]
Time frame: 8 weeks; 20 weeks
pulmonary function
diffusing capacity of the lung for carbon monoxide (DLCO) \[velocity\]
Time frame: 8 weeks; 20 weeks
Respiratory muscle strength
maximum inspiratory pressure(MIP), maximum expiratory pressure(MEP)
Time frame: 8 weeks; 20 weeks
Short Physical Performance Battery(SPPB)
Test for health-related physical performance
Time frame: 8 weeks; 20 weeks
modified British medical research council(mMRC)
It is a self-reported symptom questionnaire ranging from 0-4 score, higher scores mean a worse outcome.
Time frame: 8 weeks; 20 weeks
COPD assessment test(CAT)
It is a self-reported quality of life questionnaire ranging from 0-10 score, higher scores mean a worse outcome.
Time frame: 8 weeks; 20 weeks
St. George's Respiratory Questionnaire (SGRQ)
It is a self-reported symptom questionnaire ranging from 0-100 score, higher scores mean a worse outcome.
Time frame: 8 weeks; 20 weeks
Hospital Anxiety and Depression Scale(HADS)
It is a self-reported psychological status questionnaire ranging from 0-42 score, higher scores mean a worse outcome.
Time frame: 8 weeks; 20 weeks
Start is estimated for Nov 2023; primary completion for Aug 2024, 9 months later.
Of 796 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 9 months is below that.
Counting every sponsor, half of 848 studies reached it within 24 months; a quarter within 11 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
China-Japan Friendship Hospital →